Search

Your search keyword '"Teschler, H."' showing total 656 results
Start Over Author "Teschler, H."
656 results on '"Teschler, H."'

51. MOLECULAR ANALYSIS OF STAPHYLOCOCCUS AUREUS ISOLATES FROM AN ONGOING PROSPECTIVE OBSERVATIONAL LONGITUDINAL MULTICENTER STUDY DETERMINING STAPHYLOCOCCUS AUREUS AIRWAY COLONIZATION OR INFECTION IN CYSTIC FIBROSIS PATIENTS: 307

Author

Braun, N., Duebbers, A., Kuester, P., Ellemunter, H., Heuer, E., Sextro, W., Junge, S., Tuemmler, B., Mellies, U., Teschler, H., Mainz, J. G., Riethmueller, J., Graepler-Mainka, U., Koerner-Rettberg, C., Ballmann, M., Szczepanski, R., Wald, A., Wisbauer, M., Adelsberger, D., Staab, D., Wollschläger, B., Hammermann, J., Peters, G., Becker, K., and Kahl, B. C.

Published
2011

79. Cheyne Stokes Respiration Characteristics In Systolic Heart Failure Patients Experiencing A Primary Endpoint Event: A Serve-Hf Substudy Analysis

Author

Javed, F., Tamisier, R., Pepin, J. L., Cowie, M., Wegscheider, K., Angermann, C., D'Ortho, M-P, Erdmann, E., Simonds, A. K., Somers, V. K., Teschler, H., Armitstead, J., Levy, P., Woehrle, H., Javed, F., Tamisier, R., Pepin, J. L., Cowie, M., Wegscheider, K., Angermann, C., D'Ortho, M-P, Erdmann, E., Simonds, A. K., Somers, V. K., Teschler, H., Armitstead, J., Levy, P., and Woehrle, H.

Published
2017

80. Adaptive Servo-Ventilation For Central Sleep Apnea In Systolic Heart Failure: Psg Data From The Serve-Hf Major Substudy

Author

Tamisier, R., Pepin, J. L., Cowie, M., Wegscheider, K., Vettorazzi, E., Suling, A., Angermann, C., D'Ortho, M-P, Erdmann, E., Simonds, A. K., Somers, V. K., Zannad, F., Teschler, H., Levy, P., Woehrle, H., Tamisier, R., Pepin, J. L., Cowie, M., Wegscheider, K., Vettorazzi, E., Suling, A., Angermann, C., D'Ortho, M-P, Erdmann, E., Simonds, A. K., Somers, V. K., Zannad, F., Teschler, H., Levy, P., and Woehrle, H.

Published
2017

85. Development and validation of a novel non-contact monitor of nocturnal respiration for identifying sleep-disordered breathing in patients with heart failure

Author

Savage, HO, Khushaba, RN, Zaffaroni, A, Colefax, M, Farrugia, S, Schindhelm, K, Teschler, H, Weinreich, G, Grueger, H, Neddermann, M, Heneghan, C, Simonds, A, Cowie, MR, Savage, HO, Khushaba, RN, Zaffaroni, A, Colefax, M, Farrugia, S, Schindhelm, K, Teschler, H, Weinreich, G, Grueger, H, Neddermann, M, Heneghan, C, Simonds, A, and Cowie, MR

Abstract

© 2016 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology. Aims: At least 50% of patients with heart failure (HF) may have sleep-disordered breathing (SDB). Overnight in-hospital polysomnography (PSG) is considered the gold standard for diagnosis, but a lack of access to such testing contributes to under-diagnosis of SDB. Therefore, there is a need for simple and reliable validated methods to aid diagnosis in patients with HF. The aim of this study was to investigate the accuracy of a non-contact type IV screening device, SleepMinderTM (SM), compared with in-hospital PSG for detecting SDB in patients with HF. Methods and results: The study included 75 adult patients with systolic HF and suspected SDB who underwent simultaneous PSG and SM recordings. An algorithm was developed from the SM signals, using digital signal processing and pattern recognition techniques to calculate the SM apnoea-hypopnoea index (AHI). This was then compared with expert-scored PSGAHI. The SM algorithm had 70% sensitivity and 89% specificity for identifying patients with clinically significant SDB (AHI ≥ 15/h). At this threshold, it had a positive likelihood ratio of 6.3 and a negative likelihood ratio of 0.16. The overall accuracy of the SMAHI algorithm was 85.8% as shown by the area under a receiver operator characteristic curve. The mean AHI with SM was 3.8/h (95% confidence interval 0.5–7.1) lower than that with PSG. Conclusions: The accuracy of the non-contact type IV screening device SM is good for clinically significant SDB in patients with systolic HF and could be considered as a simple first step in the diagnostic pathway.

Published
2016

88. Herz und Lunge

Author

Teschler H and Olaf Oldenburg

Subjects
medicine.medical_specialty, Lung, medicine.anatomical_structure, business.industry, Internal medicine, Cardiology, Medizin, Medicine, Cardiology and Cardiovascular Medicine, business
Published
2014

89. Inhalation treatment with glutathione in patients with cystic fibrosis: A randomized clinical trial

Author

Griese, M., Kappler, M., Eismann, C., Ballmann, M., Junge, S., Rietschel, E., van Koningsbruggen-Rietschel, S., Staab, D., Rolinck-Werninghaus, C., Mellies, U., Köhnlein, T., Wagner, T., König, S., Teschler, H., Heuer, H.E., Kopp, M., Heyder, S., Hammermann, J., Küster, P., Honer, M., Mansmann, U., Beck-Speier, I., Hartl, D., Fuchs, C., Glutathione Study Group (), and Hector, A.

Subjects
Adult, Male, Pulmonary and Respiratory Medicine, medicine.medical_specialty, Antioxidant, Cystic Fibrosis, medicine.medical_treatment, Medizin, Critical Care and Intensive Care Medicine, Placebo, Cystic fibrosis, Gastroenterology, Antioxidants, law.invention, Young Adult, chemistry.chemical_compound, Double-Blind Method, Randomized controlled trial, Inhaled Therapy, Glutathione, Clinical Trial, law, Forced Expiratory Volume, Internal medicine, Administration, Inhalation, medicine, Humans, Lung, Inhalation, business.industry, medicine.disease, Respiratory Function Tests, Surgery, Clinical trial, Treatment Outcome, medicine.anatomical_structure, chemistry, Female, business
Abstract

Rationale: Glutathione is the major antioxidant in the extracellular lining fluid of the lungs and depleted in patients with cystic fibrosis (CF). Objectives: We aimed to assess glutathione delivered by inhalation as a potential treatment for CF lung disease. Methods: This randomized, double-blind, placebo-controlled trial evaluated inhaled glutathione in subjects with CF 8 years of age and older and FEV1 of 40-90% of predicted. Subjects were randomized to receive 646 mg glutathione in 4 ml (n = 73) or placebo (n = 80) via an investigational eFlow nebulizer every 12 hours for 6 months. Measurements and Main Results: FEV1 (absolute values), both as pre-post differences (P = 0.180) and as area under the curves (P = 0.205), were the primary efficacy endpoints, and were not different between the glutathione group and the placebo group over the 6-month treatment period. Exploratory analysis showed an increase of FEV1 from baseline over placebo of 100 ml or 2.2% predicted; this was significant at 3 months, but not later. Subjects receiving glutathione had neither fewer pulmonary exacerbations, nor better scores for quality of life. Whereas increased glutathione and metabolites in sputum demonstrated significant delivery to the lungs, there was no indication of diminished oxidative stress to proteins or lipids, and no evidence for anti-inflammatory or antiproteolytic actions of glutathione supplemented to the airways. The adverse event incidence was similar between glutathione and placebo. Conclusions: Inhaled glutathione in the dose administered did not demonstrate clinically relevant improvements in lung function, pulmonary exacerbation frequency, or patient-reported outcomes. Glutathione delivery to the airways was not associated with changes in markers of oxidation, proteolysis, or inflammation. Clinical trial registered with www.clinicaltrials.gov (NCT00506688) and https://eudract.ema.europa.eu/index.html (EudraCT 2005-003870-88).

Published
2013

Catalog

Books, media, physical & digital resources
See catalog results